Overexpression of minichromosome maintenance protein 10 in medulloblastoma and its clinical implications

Overexpression of minichromosome maintenance (MCM) proteins 2, 3, and 7 is associated with migration and invasion in medulloblastoma (MB). However, expression profiling of all prereplication complex (pre‐RC) has not been addressed in MBs.

[1]  Peir-In Liang,et al.  MCM10 overexpression implicates adverse prognosis in urothelial carcinoma , 2016, Oncotarget.

[2]  Giles W. Robinson,et al.  Medulloblastoma—translating discoveries from the bench to the bedside , 2014, Nature Reviews Clinical Oncology.

[3]  B. Stillman,et al.  Structural and mechanistic insights into Mcm2–7 double-hexamer assembly and function , 2014, Genes & development.

[4]  B. Tannous,et al.  Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo , 2014, Oncogene.

[5]  I. Symeonidou,et al.  Licensing of DNA replication, cancer, pluripotency and differentiation: an interlinked world? , 2014, Seminars in cell & developmental biology.

[6]  A. Riera,et al.  Helicase loading: how to build a MCM2-7 double-hexamer. , 2014, Seminars in cell & developmental biology.

[7]  A. Bielinsky,et al.  MCM10: one tool for all-Integrity, maintenance and damage control. , 2014, Seminars in cell & developmental biology.

[8]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[9]  C. Hawkins,et al.  Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma , 2014, Pediatric blood & cancer.

[10]  J. Walter,et al.  Prereplication-complex formation: a molecular double take? , 2014, Nature Structural &Molecular Biology.

[11]  S. S. Yadav,et al.  Over Expression of Minichromosome Maintenance Genes is Clinically Correlated to Cervical Carcinogenesis , 2013, PloS one.

[12]  P. Carmeliet,et al.  Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma , 2013, Cell.

[13]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[14]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[15]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[16]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[17]  D. Di Paola,et al.  Comparative analysis of pre‐replication complex proteins in transformed and normal cells , 2012, Journal of cellular biochemistry.

[18]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[19]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[20]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Wang,et al.  Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion , 2010, Oncogene.

[22]  M. Méchali,et al.  Eukaryotic DNA replication origins: many choices for appropriate answers , 2010, Nature Reviews Molecular Cell Biology.

[23]  G. Riggins,et al.  Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. , 2010, Neuro-oncology.

[24]  T. Wurdinger,et al.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. , 2010, Journal of proteome research.

[25]  Z. Kelman,et al.  Alternative Mechanisms for Coordinating Polymerase α and MCM Helicase , 2009, Molecular and Cellular Biology.

[26]  E. Lalli,et al.  DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells , 2008, Oncogene.

[27]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[28]  T. Merchant,et al.  Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Jong Hoon Park,et al.  Knockdown of human MCM10 activates G2 checkpoint pathway. , 2008, Biochemical and biophysical research communications.

[30]  R. Versteeg,et al.  Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. , 2007, European journal of cancer.

[31]  A. Bielinsky,et al.  Human Mcm10 regulates the catalytic subunit of DNA polymerase-alpha and prevents DNA damage during replication. , 2007, Molecular biology of the cell.

[32]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[33]  K. Ness,et al.  Physical performance limitations and participation restrictions among cancer survivors: a population-based study. , 2006, Annals of epidemiology.

[34]  Amar Gajjar,et al.  Late neurocognitive sequelae in survivors of brain tumours in childhood. , 2004, The Lancet. Oncology.

[35]  Anindya Dutta,et al.  DNA replication in eukaryotic cells. , 2002, Annual review of biochemistry.